Abstract:In addition to the role of skeletal muscle in movement and locomotion, muscle plays a critical role in a broad array of metabolic processes that can contribute to improved health or risk of disease. The age-associated loss of muscle has been termed sarcopenia. The muscle is the primary site of insulin-stimulated glucose disposal and the largest component of basal metabolic rate, directly and indirectly affects bone density, produces myokines with pleiotropic effect on muscle and other tissues including the brain, and stores essential amino acids essential for the maintenance of protein synthesis during periods of reduced food intake and stress. As such, not surprisingly deterioration of skeletal muscle health, typically operationalized as decline of muscle mass and muscle strength is both a powerful risk factor and main consequence of chronic diseases, disability, and loss of independence, and it is one of the strongest risk factors for mortality. However, skeletal muscle remains one of the most plastic of all tissues, with rapid changes in rates of protein synthesis and degradation in response to physical activity and inactivity, inflammation, and nutritional and hormonal status. This has made the development of pharmacological therapies to increase muscle mass (or prevent loss), an important goal for decades. However, while remarkable advances in the understanding of molecular and cellular regulation of muscle protein metabolism have occurred recently, there are no approved drugs for the treatment of sarcopenia, the loss of skeletal muscle affecting millions of older people. The goal of this paper is to describe the possible reasons for the lack of new and effective pharmacotherapies to treat one of the most important risk factors for age-associated disease and loss of independence.

Muscle wasting and sarcopenia in heart failure and beyond: update 2017

Research Advances in Muscle Stem Cells and Sarcopenia

Muscle wasting in ageing and chronic illness

Biological basis and treatment of frailty and sarcopenia

Muscle wasting and cachexia in heart failure: mechanisms and therapies

New Insights into the Pathogenesis and Treatment of Sarcopenia in Chronic Heart Failure

Exercise and nutritional interventions on sarcopenia and frailty in heart failure: a narrative review of systematic reviews and meta‐analyses

Current and investigational medications for the treatment of sarcopenia

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies

A Narrative Review of the Diagnosis and Treatment of Sarcopenia and Malnutrition in Patients with Heart Failure

Recent advances in cell-based and cell-free therapeutic approaches for sarcopenia

Rehabilitation of Older Adults with Sarcopenia: From Cell to Functioning

Muscle aging and sarcopenia: The pathology, etiology, and most promising therapeutic targets

Sarcopenia: assessment of disease burden and strategies to improve outcomes

Current understanding of sarcopenia: possible candidates modulating muscle mass

Gut microbiota in sarcopenia and heart failure

Sarcopenia and Cardiovascular Diseases

Sarcopenia: no consensus, no diagnostic criteria, and no approved indication-How did we get here?

The Current Landscape of Pharmacotherapies for Sarcopenia

Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials

Lost in translation: challenges of current pharmacotherapy for sarcopenia